We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
Cap. Flow
-$1B
Cap. Flow %
-12.68%
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35

Top Buys

Rank Stock Value
1
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$194M
2
BBIO icon
BridgeBio Pharma
BBIO
+$68.7M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$68.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$62.1M
5
SWTX
SpringWorks Therapeutics
SWTX
+$52.6M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$116M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$100M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$90.4M
4
NVTA
Invitae Corporation
NVTA
+$87.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$87.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.08%
2 Financials 0.47%
3 Industrials 0.2%
4 Consumer Discretionary 0.02%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
151
Novavax
NVAX
$1.22B
– –
-1,043,000
Closed -$116M
PPH icon
152
PUT
VanEck Pharmaceutical ETF
PPH
$990M
– –
-200,000
Closed -$13.3M
PTGX icon
153
Protagonist Therapeutics
PTGX
$8.68B
– –
-203,591
Closed -$4.1M
REGN icon
154
Regeneron Pharmaceuticals
REGN
$73.1B
– –
-55,175
Closed -$26.7M
RGEN icon
155
Repligen
RGEN
$6.96B
– –
-97,500
Closed -$18.7M
RVMD icon
156
Revolution Medicines
RVMD
$38.9B
– –
-224,224
Closed -$8.88M
SAGE
157
DELISTED
Sage Therapeutics
SAGE
– –
-440,000
Closed -$38.1M
SCYX icon
158
SCYNEXIS
SCYX
$37.2M
– –
-300,000
Closed -$18.4M
SHC icon
159
Sotera Health
SHC
$4.99B
– –
-300,000
Closed -$8.23M
WVE icon
160
Wave Life Sciences
WVE
$1.12B
– –
-2,500,000
Closed -$19.7M
XBI icon
161
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-200,000
Closed -$28.2M
ZNTL icon
162
Zentalis Pharmaceuticals
ZNTL
$335M
– –
-1,050,003
Closed -$54.5M
NSTG
163
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-337,800
Closed -$22.6M
AMRS
164
DELISTED
Amyris Inc.
AMRS
– –
-3,333,332
Closed -$20.6M
MTEM
165
DELISTED
Molecular Templates, Inc.
MTEM
– –
-27,455
Closed -$3.87M
IPOF
166
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
– –
-40,000
Closed -$671K
OTLKW
167
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
– –
-420,875
Closed -$93K
SCPE.U
168
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
– –
-1,000,000
Closed -$11M
UROV
169
DELISTED
Urovant Sciences Ltd.
UROV
– –
-3,116,831
Closed -$50.3M
LGVW.U
170
DELISTED
Longview Acquisition Corp. Units, each consisting of one share of Class A common stock, and one-thir
LGVW.U
– –
-700,000
Closed -$15.2M
EIDX
171
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-686,922
Closed -$90.4M
3 4 5 6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.

  • Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
  • Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
  • Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
  • Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
  • Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
  • Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.